NHI heads into its Q2 print with a notable short-side rebuild underway, even as borrowing conditions remain relaxed and options positioning stays only modestly defensive.
Short interest has climbed sharply over the past week — up 11.5% to 5.3% of the free float — a meaningful move for a healthcare REIT with historically stable positioning. The rebuild is more striking in context: shorts had roughly halved their exposure through late July, dropping from around 4.2 million shares in mid-July to 2.2 million by July 24, before reversing course in the final week. Despite that renewed accumulation, the lending market is not under pressure. Availability is running at 349%, meaning more than three shares remain available to borrow for every share currently lent out, and cost to borrow has eased to 0.43% — down 26% over the past month — placing NHI firmly in easy-to-short territory. Options positioning reinforces a mild defensive lean: the put/call ratio is 1.31, modestly above its 20-day average of 1.20, but with a z-score near zero, it falls well short of a stressed reading. The stock itself has drifted lower, down 2.4% on the week and 1.5% on the day to $74.15, underperforming most close peers — AHR gained 3.7% Monday, added 1.2%, and edged up 0.4%.
The Street has quietly turned more cautious on the name. Multiple analysts trimmed price targets in June — Deutsche Bank lowered to $80, BMO Capital to $80 from $90, and Truist Securities to $81 from $89 — while all maintained their positive-to-neutral ratings. The consensus mean target of $82.88 implies roughly 12% upside from current levels, but the direction of target revisions heading into this print is uniformly downward. Bears point to lowered 2026–2027 FFO estimates tied to dilution from portfolio sales, where proceeds repaid debt rather than being redeployed into growth assets, and to concentrated operator exposure that amplifies idiosyncratic risk. Bulls counter that NHI's low leverage, deep investment pipeline, and below-average cost of capital position it well for a multi-year recovery as senior housing demand builds — and that the stock at $74 represents an attractive entry into that thesis. Earnings momentum factor scores rank in the 100th percentile on both 30-day and 12-month forward metrics, which supports the bull case, though the EPS surprise rank at 48 suggests the company does not consistently clear the bar on a quarterly basis.
One institutional flow point adds context. BlackRock added nearly 3.9 million shares in its most recent filing, lifting its stake to 18% of shares outstanding — a meaningful accumulation from one of the stock's largest holders. On the insider side, CEO D. Eric Mendelsohn purchased 1,500 shares in early June at $68.84, the most recent open-market buy from the C-suite, following a cluster of smaller sells in May at $73. The net 90-day insider flow is modestly positive at roughly 3,400 shares, though the dollar amounts are small relative to the company's size. Past earnings reactions have been consistently negative in the near term: the last three prints produced day-one moves of -1.2%, -1.2%, and -2.4%, with the May event extending to a -8.8% five-day loss.
The print will test whether NHI's investment pipeline and balance sheet story can offset continued FFO dilution from the NHC portfolio exit — and whether the company can articulate a credible timeline for rebuilding normalized income to pre-sale levels.
See the live data behind this article on ORTEX.
Open NHI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
